Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
Amikacin Monotherapy for Sepsis Caused by Panresistant <i>Pseudomonas aeruginosa</i>Brice Layeux, Frédérique Jacobs, Fabio Silvio Taccone et al.|Antimicrobial Agents and Chemotherapy|2010Cited by 50